SciSparc Expands Psychedelic IP Portfolio with MDMA-PEA Patent for PTSD Treatment
Event summary
- SciSparc's subsidiary NeuroThera published a U.S. patent application for MDMA-N-acylethanolamines combination therapy for PTSD, anxiety, and eating disorders.
- The patent is part of a collaboration with Clearmind, resulting in 13 published patent applications globally.
- FDA finalized guidance on July 14, 2026, explicitly including MDMA in its definition of psychedelic drugs.
- The patent explores potential effects of PEA on MDMA's therapeutic potency, dosing, side effects, and therapeutic window.
The big picture
This patent filing comes amid rising federal support for psychedelic innovation, with the FDA's recent guidance providing a clearer regulatory pathway. SciSparc's strategic collaboration with Clearmind positions it to capitalize on the growing acceptance of psychedelic-assisted therapies, particularly for mental health conditions like PTSD. The combination of MDMA with PEA represents a novel approach that could differentiate SciSparc's offerings in a competitive market.
What we're watching
- Regulatory Tailwinds
- How FDA's explicit inclusion of MDMA in psychedelic drug guidance will accelerate development timelines for combination therapies.
- IP Portfolio Value
- Whether the growing patent portfolio will enhance SciSparc's strategic position in the psychedelic therapeutics space.
- Clinical Validation
- The pace at which NeuroThera and Clearmind can translate this IP into successful clinical trials for PTSD treatment.
Related topics